MetaCap

Who Owns Keros Therapeutics Stock?

NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.08-0.31 (-2.72%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
99.50%
Institutional holders
194
  • Institutions 95.4%
  • Insiders 4.6%
  • Public and other 0.0%

Who owns Keros Therapeutics stock?

Institutional investors own about 99.5% of Keros Therapeutics's shares, spread across 194 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.62% of KROS.

The largest institutional holders are Blackrock Inc. (14.24%), Nantahala Capital Management, LLC (7.19%) and AQR Capital Management, LLC (4.93%). Together, the top 10 institutions control 51.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their KROS positions and 2 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of KROS

Keros Therapeutics top institutional holders
InstitutionShares% HeldChange
Blackrock Inc.2.79M14.24%+15.9%
Nantahala Capital Management, LLC1.41M7.19%+3.7%
AQR Capital Management, LLC967.86K4.93%+138.1%
Vanguard Capital Management LLC833.60K4.25%+0.3%
Orbimed Advisors LLC.759.15K3.87%0.0%
Mackenzie Financial Corporation742.84K3.79%+18.2%
Federated Hermes, Inc.707.05K3.60%+0.9%
Vanguard Portfolio Management LLC652.63K3.33%-4.3%
Madison Avenue Partners, LP626.58K3.19%0.0%
Qube Research & Technologies Ltd608.84K3.10%-16.0%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of KROS

Keros Therapeutics top fund holders
FundShares% Held
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund595.32K3.03%
iShares Trust-iShares Russell 2000 ETF477.30K2.43%
BlackRock Funds-BlackRock Advantage Small Cap Core Fund454.75K2.32%
Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund382.34K1.95%
VANGUARD HORIZON FUNDS-Vanguard Strategic Small-Cap Equity Fund258.66K1.32%
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund220.85K1.13%
TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund190.04K0.97%
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund178.52K0.91%
iShares Trust-iShares Russell 2000 Value ETF175.34K0.89%
Vanguard Explorer Fund171.15K0.87%

Frequently asked questions

Who is the largest shareholder of Keros Therapeutics?

Blackrock Inc. is the largest institutional shareholder of KROS, owning 14.24% of shares outstanding (2.79M shares) as of its latest 13F filing.

What percentage of Keros Therapeutics is owned by institutions?

Institutions own about 99.5% of KROS shares and 104.3% of the public float.

How much of Keros Therapeutics do insiders own?

Insiders, such as officers and directors, own about 4.62% of KROS shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related